Fifteen patients with recurrent primary brain tumors were treated with fludarabine phosphate. There were no responses seen. Toxicity was mild and primarily hematological. Fludarabine phosphate would appear to be ineffective in recurrent gliomas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00000421-198810000-00015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design of an innovative aptasensor for the detection of chemotherapeutic drug Fludarabine phosphate.
Sci Rep
November 2024
Department of Chemistry, Alfaisal University, Al Zahrawi Street, Al Maather, Al Takhassusi Rd, Riyadh, 11355, Saudi Arabia.
Monitoring the concentration of Fludarabine phosphate, a standard chemotherapeutic drug widely used in cancer treatment, is vital for ensuring the drug's safety and effectiveness, tailoring treatments to individual needs, and consequently improving overall patient outcomes. Regarding the limitations of conventional techniques in terms of complexity, large time measurements, and a high cost, there is an urgent need to develop simple, rapid, and cost-effective devices. In this paper, we report the design of an aptasensor for the specific and selective detection of Fludarabine.
View Article and Find Full Text PDFCharacterization of Chemical Interactions between Clinical Drugs and the Oral Bacterium, , via Bioactivity-HiTES.
ACS Chem Biol
April 2024
Department of Biopharmaceutical Convergence, Sungkyunkwan University, Suwon 16419, Republic of Korea.
In the field of natural product research, the rediscovery of already-known compounds is one of the significant issues hindering new drug development. Recently, an innovative approach called bioactivity-HiTES has been developed to overcome this limitation, and several new bioactive metabolites have been successfully characterized by this method. In this study, we applied bioactivity-HiTES to , the human oral bacterium, with 3120 clinical drugs as potential elicitors.
View Article and Find Full Text PDFCocktail of lipophilic and hydrophilic chemotherapeutics in high-load core@shell nanocarriers to treat pancreatic tumours.
Nanoscale Adv
January 2024
Institute for Inorganic Chemistry (IAC), Karlsruhe Institute of Technology (KIT) Engesserstraße 15 76131 Karlsruhe Germany
ITC/Toc@Gd(FLP) core@shell nanocarriers with a chemotherapeutic cocktail of lipophilic irinotecan (ITC) as the particle core and hydrophilic fludarabine phosphate (FLP) in the particle shell are realized. They are prepared a microemulsion approach with ITC dissolved in tocopherol (Toc) as droplet phase and stabilized by water-insoluble Gd(FLP). The synthesis can be followed by zeta-potential analysis.
View Article and Find Full Text PDFMacrophage neogenin deficiency exacerbates myocardial remodeling and inflammation after acute myocardial infarction through JAK1-STAT1 signaling.
Cell Mol Life Sci
October 2023
Department of Cardiology, Renmin Hospital of Wuhan University, Department of Geriatrics, Zhongnan Hospital of Wuhan University, Wuhan University, 238 Jiefang Road, Wuhan, 430060, China.
Immune response plays a crucial role in post-myocardial infarction (MI) myocardial remodeling. Neogenin (Neo1), a multifunctional transmembrane receptor, plays a critical role in the immune response; however, whether Neo1 participates in pathological myocardial remodeling after MI is unclear. Our study found that Neo1 expression changed significantly after MI in vivo and after LPS + IFN-γ stimulation in bone marrow-derived macrophages (BMDMs) in vitro.
View Article and Find Full Text PDFSLC25A51 promotes tumor growth through sustaining mitochondria acetylation homeostasis and proline biogenesis.
Cell Death Differ
August 2023
Department of Medical Genetics, Center for Medical Genetics, Peking University Health Science Center, Beijing, 100191, China.
Solute carrier family 25 member 51 (SLC25A51) was recently identified as the mammalian mitochondrial NAD+ transporter essential for mitochondria functions. However, the role of SLC25A51 in human disease, such as cancer, remains undefined. Here, we report that SLC25A51 is upregulated in multiple cancers, which promotes cancer cells proliferation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!